MX2020013290A - Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo. - Google Patents
Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo.Info
- Publication number
- MX2020013290A MX2020013290A MX2020013290A MX2020013290A MX2020013290A MX 2020013290 A MX2020013290 A MX 2020013290A MX 2020013290 A MX2020013290 A MX 2020013290A MX 2020013290 A MX2020013290 A MX 2020013290A MX 2020013290 A MX2020013290 A MX 2020013290A
- Authority
- MX
- Mexico
- Prior art keywords
- amino
- syndrome
- carboxylic acid
- difluoromethylenyl
- cyclopent
- Prior art date
Links
- CBSRETZPFOBWNG-UCORVYFPSA-N (1s,3s)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid Chemical compound N[C@H]1C[C@@H](C(O)=O)CC1=C(F)F CBSRETZPFOBWNG-UCORVYFPSA-N 0.000 title abstract 2
- FBLNZOCTNRXJQD-YFKPBYRVSA-N N[C@H]1C=C(CC1=C(F)F)C(O)=O Chemical compound N[C@H]1C=C(CC1=C(F)F)C(O)=O FBLNZOCTNRXJQD-YFKPBYRVSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000012239 Developmental disease Diseases 0.000 title 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 title 1
- 229960005318 vigabatrin Drugs 0.000 title 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 2
- 208000009575 Angelman syndrome Diseases 0.000 abstract 1
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 208000004706 Jacobsen Distal 11q Deletion Syndrome Diseases 0.000 abstract 1
- 208000029279 Jacobsen Syndrome Diseases 0.000 abstract 1
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract 1
- 206010049644 Williams syndrome Diseases 0.000 abstract 1
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract 1
- 201000003415 fragile X-associated tremor/ataxia syndrome Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan métodos y composiciones para usarse en el tratamiento del síndrome del X frágil, síndrome de Angelman, síndrome de temblor/ataxia asociado al X frágil, Trastorno del Espectro Autista, síndrome de Asperger, trastorno generalizado del desarrollo no especificado de otro manera, trastorno desintegrativo infantil, síndrome de Williams o síndrome de Jacobsen con un compuesto de fórmula 1 como se describe en la presente, ácido (S)-3-amino-4-(difluorometilenil)ciclopent-1-eno-1 -carboxílico, ácido (1S,3S)-3-amino-4-(difluorometilideno)ciclopen tano-1-carboxílico o vagabatrina, o sales farmacéuticamente aceptables de cualquiera de los anteriores.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862681913P | 2018-06-07 | 2018-06-07 | |
| PCT/US2019/035934 WO2019236938A1 (en) | 2018-06-07 | 2019-06-07 | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013290A true MX2020013290A (es) | 2021-04-29 |
Family
ID=68765508
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013290A MX2020013290A (es) | 2018-06-07 | 2019-06-07 | Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo. |
| MX2023006497A MX2023006497A (es) | 2018-06-07 | 2020-12-07 | Uso de acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006497A MX2023006497A (es) | 2018-06-07 | 2020-12-07 | Uso de acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10813899B2 (es) |
| EP (1) | EP3813816B1 (es) |
| JP (1) | JP7387179B2 (es) |
| KR (1) | KR102744830B1 (es) |
| CN (1) | CN112770739B (es) |
| AU (1) | AU2019280980B2 (es) |
| CA (1) | CA3102786A1 (es) |
| ES (1) | ES2948263T3 (es) |
| IL (2) | IL304270B2 (es) |
| MX (2) | MX2020013290A (es) |
| PL (1) | PL3813816T3 (es) |
| WO (1) | WO2019236938A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL304270B2 (en) | 2018-06-07 | 2024-10-01 | Ovid Therapeutics Inc | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders |
| WO2024173747A1 (en) * | 2023-02-17 | 2024-08-22 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes |
| WO2024173750A2 (en) * | 2023-02-17 | 2024-08-22 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| WO2005120496A2 (en) | 2004-05-24 | 2005-12-22 | Regents Of The University Of California | TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE |
| WO2009033818A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| WO2011106692A2 (en) | 2010-02-25 | 2011-09-01 | Northwestern University | Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid |
| US20130230586A1 (en) | 2010-10-02 | 2013-09-05 | Link Research & Grants Corporation | Treatment of Tinnitus and Related Auditory Dysfunctions |
| US20140315992A1 (en) | 2011-07-07 | 2014-10-23 | The Children's Hospital Of Philadelphia | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism |
| CA2862816A1 (en) | 2012-01-27 | 2013-08-01 | Catalyst Pharmaceutical Partners | Method of treating tourette's disorder with gaba-aminotransferase inactivators |
| TW201605443A (zh) * | 2013-09-09 | 2016-02-16 | 亞克柏拉有限公司 | 治療ｘ染色體脆折症及相關病症的方法 |
| US20150224164A1 (en) | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| EP3215144B1 (en) | 2014-11-07 | 2021-04-28 | Northwestern University | Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma |
| US20170348232A1 (en) * | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| EP3341355B1 (en) | 2015-10-09 | 2020-09-30 | Northwestern University | (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma |
| US10632088B2 (en) | 2016-10-10 | 2020-04-28 | Northwestern University | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria |
| JP7607302B2 (ja) | 2017-02-08 | 2024-12-27 | オービッド・セラピューティクス・インコーポレイテッド | 発作性障害およびプラダー・ウィリー症候群の治療方法 |
| CN111432814B (zh) * | 2017-11-14 | 2024-05-14 | 爱思开生物制药株式会社 | 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途 |
| IL278932B2 (en) | 2018-05-25 | 2024-03-01 | Univ Northwestern | PROCESS FOR THE SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-l-ENE-l-CARBOXYLIC ACID |
| IL304270B2 (en) | 2018-06-07 | 2024-10-01 | Ovid Therapeutics Inc | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders |
-
2019
- 2019-06-07 IL IL304270A patent/IL304270B2/en unknown
- 2019-06-07 IL IL279220A patent/IL279220B2/en unknown
- 2019-06-07 US US16/434,300 patent/US10813899B2/en active Active
- 2019-06-07 JP JP2020567857A patent/JP7387179B2/ja active Active
- 2019-06-07 MX MX2020013290A patent/MX2020013290A/es unknown
- 2019-06-07 ES ES19815892T patent/ES2948263T3/es active Active
- 2019-06-07 PL PL19815892.5T patent/PL3813816T3/pl unknown
- 2019-06-07 CA CA3102786A patent/CA3102786A1/en active Pending
- 2019-06-07 CN CN201980052607.5A patent/CN112770739B/zh active Active
- 2019-06-07 KR KR1020217000541A patent/KR102744830B1/ko active Active
- 2019-06-07 AU AU2019280980A patent/AU2019280980B2/en active Active
- 2019-06-07 WO PCT/US2019/035934 patent/WO2019236938A1/en not_active Ceased
- 2019-06-07 EP EP19815892.5A patent/EP3813816B1/en active Active
-
2020
- 2020-10-16 US US17/072,511 patent/US11660277B2/en active Active
- 2020-12-07 MX MX2023006497A patent/MX2023006497A/es unknown
-
2023
- 2023-04-19 US US18/302,997 patent/US12285397B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL279220B1 (en) | 2023-08-01 |
| US20210100763A1 (en) | 2021-04-08 |
| CA3102786A1 (en) | 2019-12-12 |
| KR102744830B1 (ko) | 2024-12-19 |
| US12285397B2 (en) | 2025-04-29 |
| IL279220A (en) | 2021-01-31 |
| ES2948263T3 (es) | 2023-09-07 |
| EP3813816A4 (en) | 2021-06-23 |
| IL304270A (en) | 2023-09-01 |
| US10813899B2 (en) | 2020-10-27 |
| IL279220B2 (en) | 2023-12-01 |
| WO2019236938A1 (en) | 2019-12-12 |
| EP3813816B1 (en) | 2023-06-07 |
| US20190374492A1 (en) | 2019-12-12 |
| EP3813816C0 (en) | 2023-06-07 |
| EP3813816A1 (en) | 2021-05-05 |
| KR20210035802A (ko) | 2021-04-01 |
| MX2023006497A (es) | 2023-06-21 |
| JP2021527053A (ja) | 2021-10-11 |
| IL304270B2 (en) | 2024-10-01 |
| US11660277B2 (en) | 2023-05-30 |
| CN112770739B (zh) | 2023-12-12 |
| JP7387179B2 (ja) | 2023-11-28 |
| IL304270B1 (en) | 2024-06-01 |
| CN112770739A (zh) | 2021-05-07 |
| US20230255914A1 (en) | 2023-08-17 |
| AU2019280980B2 (en) | 2025-02-27 |
| AU2019280980A1 (en) | 2021-01-07 |
| PL3813816T3 (pl) | 2023-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002004A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| MX2020013373A (es) | Compuestos de naftiridinona utiles como activadores de celulas t. | |
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| MX385731B (es) | Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| MX2019004019A (es) | Pirrolidinas sustituidas como moduladores cftr. | |
| PH12015500776A1 (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2019004578A (es) | Oxisteroles y metodos de uso de los mismos. | |
| EA202090604A1 (ru) | Хроманмонобактамовые соединения для лечения бактериальных инфекций | |
| NZ741093A (en) | Compounds, compositions, and methods for modulating cftr | |
| PH12015500817A1 (en) | Methylene linked quinolinyl modulators of ror-gamma-t | |
| MX2018010878A (es) | Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| WO2014172188A3 (en) | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors | |
| MX2020013290A (es) | Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo. | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| TR201902057T4 (tr) | Tetrasiklin bileşikleri. | |
| MX394245B (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| PH12019502509A1 (en) | Compounds and methods for treating bacterial infections | |
| MX2019011908A (es) | Macrociclos de peptidos anti-bacterianos y uso de los mismos. | |
| MX2024015245A (es) | Compuestos utiles como moduladores de la autofagia mediada por chaperonas | |
| MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. |